Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients a randomized trial

Abstract

One hundred seventeen postmenopausal advanced breast cancer patients previously untreated with chemotherapy were randomized to receive: (A) cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF), (B) CMF and tamoxifen (TMX), and (C) CMF and medroxyprogesterone (MAP). Treatments B and C induced a greater proportion of responses than treatment A. No effect was identified on the number of complete responses. After treatment failure, patients from groups A and C received Adriamycin (doxorubicin) (ADX) vincristine (VCR), and TMX and patients from group B received ADM, VCR, and MAP. No differences were found between the branches in the response rates to the second protocol. Responders to both treatments had a longer survival experience than nonresponders or responders to only one of the treatments. Survival was independent of the treatment group. Copyright © 1985 American Cancer Society